GST Department Launches Search, Inspection at Cipla's Maharashtra Facilities

Published On 2026-02-08 06:00 GMT | Update On 2026-02-08 06:00 GMT

New Delhi: Cipla Limited has informed stock exchanges that the Goods and Services Tax (GST) Department, Maharashtra, has initiated inspection and search proceedings at certain facilities and offices of the company located in Maharashtra.

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In a regulatory filing, Cipla stated that the inspection and search proceedings were initiated by the Deputy Commissioner of State Tax, Maharashtra, on the same day. The proceedings commenced at 12:30 hours and are currently ongoing. The company clarified that it is extending full cooperation and assistance to the authorities during the process.

According to the details provided, the action has been initiated under Section 67 of the Maharashtra Goods and Services Tax Act, 2017, covering inspection under sub-section (1) and search under sub-section (2) of the said provision. The inspection and search relate, inter alia, to areas concerning payment of tax, claim of input tax credit, and refund matters, among other aspects.

Also Read: Cipla Names Arun Kakatkar as Global Chief People Officer

Cipla further stated that the disclosure has been made in compliance with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, which prescribes the format and details required to be disclosed for such regulatory actions.

Importantly, the company has clarified that the initiation of the inspection and search proceedings has no financial impact on Cipla. It also noted that the ongoing action has not impacted the operations of the company in any manner.

Also Read: Cipla Gets CDSCO Panel Nod to Begin Phase III Study of Semaglutide Injection

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Parthika Patel

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

GST Department Launches Search, Inspection at Cipla's Maharashtra Facilities

Similar News

Sigachi Pharma CEO Gets Conditional Bail in Sangareddy Blast Case That Killed 54 Workers

Fake Liv 52, Ibugesic Plus, Cosglo Cream Seized as Bihar DCA Busts Illegal Drug Unit

Pharmacy Store Owner to Be Booked for Abetment After 20-Year-Old Attendant Found Dead in Pune

Sun Pharma Rules Out Big-Bang Acquisitions, Bets on Organic Growth and Biosimilars

Fire at Emcure Pharma's Pune Plant, Operations Temporarily Halted

Alembic Pharma Q3 FY26 Profit Slips to Rs 133 Cr After One-Time Labour Code Provision, Revenue Up 11%

Pharma Firms May Need Prior Approval for Major Drug Changes Under NDCT Draft Amendment

Aurobindo Pharma Gets 11 USFDA Observations at Eugia Unit